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A B S T R A C T   
Background: Nitrate-rich food can increase NO production and may induce positive effects on brain function. This 
study examined the feasibility of a randomized clinical trial (RCT) testing the effects of prolonged consumption 
of incremental doses of dietary nitrate (NO3
  ) in overweight and obese older participants. Secondary aims tested 
dose-dependent changes in cognitive, vascular and pulmonary functions and cerebral blood flow (CBF). 
Methods: This was a single blind, four-arm parallel RCT conducted in 60 overweight and obese older participants. 
Eligible participants were randomized to:1) high NO3
  (140 ml of beetroot juice (BJ) per day, ~800 mg of NO3
  / 
day), 2) moderate NO3
  (70 ml of BJ per day, ~400 mg of NO3
  /day), 3) low NO3
  (70 ml on alternate days, ~400 
mg of NO3
  ) or 4) NO3
  depleted (70 ml on alternate days, ~0.001 mg of NO3). Measurements of cognitive, 
vascular and pulmonary functions and CBF were conducted at baseline and 13-weeks NO3
  intake was assessed by 
six 24-h recalls, and by measuring NO3
  intake biomarkers. Feasibility was assessed by obtaining qualitative 
feedback and evaluating trial recruitment, retention, compliance with study visits and measurement protocols. 
Results: Participant recruitment started in July 2018 and ended in April 2019. Of all the recruitment strategies 
that were used, advertisement of the study via Facebook generated the highest response rate. Sixty-two partic-
ipants consented and were enrolled. Overall, characteristics of included participants matched our recruitment 
criteria. 
Conclusion: The findings from this study provide evidence of the acceptability and feasibility of an intervention 
investigating the effects of incremental doses of high-nitrate BJ over a prolonged period. 
Trial registration: The intervention study was registered with clinical trial ISRCTN registry (ISRCTN14746723) on 
27 December 2018.   
1. Introduction 
Nitric oxide (NO) is a gaseous signalling molecule which is produced 
primarily via the activity of inter-connected enzymatic and non- 
enzymatic pathways [1]. Reduced NO synthesis is associated with 
learning and memory impairment in rats which is improved by L-argi-
nine supplementation [2]. In humans, reduced NO availability is asso-
ciated with increased risk of neurodegenerative diseases such as 
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Alzheimer Disease [3]. Asymmetric dimethylarginine (ADMA) is an 
endogenous inhibitor of NO synthase (NOS) and higher plasma ADMA 
concentrations are associated with reduced NO synthesis, endothelial 
dysfunction and increased risk for cardiovascular diseases [4,5]. 
NO production decreases with age as a result of decreased efficiency 
of the enzymatic synthetic pathway, and is reduced further in older 
people with metabolic and cardiovascular impairment [6,7]. Key char-
acteristics of vascular ageing include decreased NO production, reduced 
endothelial integrity and increased arterial stiffness; established risk 
factors for the development of atherosclerosis [8]. Nutritional and life-
style interventions capable of maintaining, or restoring, normal NO 
production may reduce the risk of atherosclerosis and cardiovascular 
diseases. In turn, this might help to reduce the risk of cognitive 
dysfunction and dementia since, among older people, better cardiovas-
cular health is associated with a lower incidence of cognitive decline and 
lower risk of dementia [9]. 
Recent studies have demonstrated that foods rich in inorganic nitrate 
(NO3
  ) can increase NO production and induce positive effects on blood 
pressure, muscular performance and brain function [10,11]. In partic-
ular, some studies have reported improvements in cognitive function 
(memory and executive performance) and motor skills after dietary NO3
 
supplementation, which appears to be mediated by augmented cerebral 
blood flow (CBF) and efficiency of cellular metabolism [12,13]. How-
ever, our recent systematic review and meta-analysis found no evidence 
that NO3
  supplementation improves cognitive function and CBF [14]. 
This systematic review identified several limitations in the current evi-
dence base including that the majority of trials were of short duration 
and conducted in healthy, normal weight participants (only one study 
supplemented inorganic nitrite had a duration of 10 weeks whereas the 
remaining trials had a duration of less than 2 weeks). Hence, the current 
evidence on the sustained effects of dietary NO3
  and nitrite (NO2
  ) on 
cognition, brain function and CBF is limited, and studies of longer 
duration and larger sample size are needed in individuals with reduced 
NO synthesis and at greater risk of endothelial dysfunction and cognitive 
impairment. 
This pilot RCT was designed primarily to determine the feasibility 
and acceptability of the protocol for a 13 weeks intervention study in 
which overweight and obese older participants were asked to consume 
different doses of NO3
  -rich beetroot juice (BJ). Secondary aims of the 
study included testing whether the different doses of dietary NO3
  result 
in different changes in cognitive, vascular and pulmonary functions and 
CBF. 
2. Methods 
2.1. Study design and randomization 
This feasibility study was designed as a randomized, single-blind, 
placebo-controlled, four-arm parallel trial with a duration of 13 
weeks. After a screening assessment for the evaluation of the inclusion 
and exclusion criteria, eligible participants were randomized to one of 
the four intervention groups. The first intervention group (Group 1) was 
asked to consume two 70 ml shots of concentrated BJ per day (400 mg of 
NO3
  per shot, Beet-it, James White Company), one every morning 
(~8am) and one each evening (~9pm). Groups 2 and 3 were asked to 
consume one shot every evening (~9pm) and every other evening 
(~9pm), respectively. Group 4 (the control group) received the placebo 
(NO3
  depleted BJ, 0.001 mg of NO3
  ) and were asked to consume a bottle 
every other evening (~9pm). The randomization pattern was generated 
using the RAND function in Excel (Excel Microsoft software, Microsoft 
corp, Redmond, WA, USA). The study adhered to the SPIRIT guidelines 
(see Table 1). 
2.2. Study setting 
The study visits were conducted at the NU-Food research facility at 
Newcastle University and the CBF measurements were performed at the 
Brain Performance Nutrition research centre at Northumbria University. 
2.3. Blinding 
This was a single-blind study as participants were not informed about 
whether they were allocated to the NO3
  -rich BJ or NO3
  -depleted BJ 
(placebo). Blinding of the researchers to the intervention was not 
possible due to the nature of the dietary interventions and study design 
as the frequency and volume of the BJ given to each participant revealed 
the nature of the interventions. 
2.4. Recruitment strategies 
Participant recruitment occurred between July 2018 and April 2019. 
Potential participants were identified through several recruitment 
strategies:  
 Flyers and posters distributed in local communities  
 Advertisements in local newspapers and newsletters  
 Emails circulated to Newcastle University members of staff 
 Search of existing databases held by Newcastle University of par-
ticipants in previous studies who had consented to be contacted to 
take part in future research studies  
 Advertisement of the study via social media (i.e., Facebook)  
 Invitation from recruited participants to friends and relatives 
2.5. Retention 
Several strategies were adopted to minimize the drop out of partic-
ipants during the study. All participants were provided with contact 
details of the lead investigator who replied promptly to participants’ 
queries. Regular emails were sent to participants to remind them to 
complete the scheduled dietary assessments using Intake24 every two 
weeks and to collect the urine and saliva samples every 4 weeks. All 
appointments were scheduled at the participants’ convenience but 
careful planning was required to ensure that time intervals between 
visits were similar between participants (deviation from scheduled ap-
pointments: 2 days). Participants received a £60 shopping voucher on 
completion of the study. 
3. Participants 
3.1. Inclusion criteria 
We aimed to recruit 60 healthy, overweight and obese ((BMI) range: 
25–40 kg/m2) male and female older participants (60–75 years). 
3.2. Exclusion criteria  
 Current participation in other clinical research studies.  
 Vegetarian.  
 Smokers.  
 Systolic BP lower than 115 mmHg and greater than 160 mmHg; 
diastolic BP lower than 70 mmHg and greater than 100 mmHg.  
 Active cancer and any diagnosis of malignant cancer in the last 5 
years  
 Excessive alcohol intake (>21 units per week) (Alcohol unit  Total 
alcohol volume (ml) * Alcohol by volume (%)/1000).  
 Allergy or intolerance to the intervention food (BJ).  
 Diagnosis of chronic or acute metabolic and inflammatory conditions 
that may interfere with the study outcomes.  
 Major surgical operations. 
 Use of prescribed psychiatric drugs (antidepressants, sedatives, an-
tipsychotics), diuretics, organic nitrates and proton pump inhibitors. 
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 Use of prescribed hormonal therapies (oestrogens, thyroxin, and 
progesterone), anti-hypertensive (Ca channel blockers, beta- 
blockers, and angiotensin-converting-enzyme (ACE) inhibitors), 
statins and any other anti-dyslipidaemic agent, if the prescription 
had started, or the dose had been started/changed, in the previous 
three months.  
 Non-prescribed dietary supplements were stopped at least for 2 
weeks before starting the trial. 
 Use of the mouthwash during the study was not allowed as it in-
terferes with the conversion of oral NO3
  into NO2
  . 
3.3. Screening and consent 
Individuals who contacted the research team and expressed an in-
terest to participate received detailed information about the study either 
by email or by post. A telephone screening was then arranged to assess 
eligibility based on date of birth, medical history and medication use 
and commitment and availability to participate to the study over a 
period of three months. If potential participants met the eligibility 
criteria at the telephone screening, they were invited to an onsite 
screening visit for further assessments to confirm the eligibility. 
During the on-site screening visit, a member of the research team 
explained the study protocol and measurement procedures and 
answered any queries from participants. Potential participants were 
asked to read and sign the consent form. Next, body weight and height 
were measured to calculate BMI and resting clinic BP was measured in 
triplicate. Participants were included in the study if BMI and BP were 
within the range specified in the study protocol. At the end of the 
screening visit, eligible participants started a familiarization session for 
the computerized cognition tasks which included the completion of 
three consecutive cognitive tasks. This aimed to minimize the risk of a 
learning effect between baseline and end of study assessments. 
4. Outcome measures 
4.1. Primary 
The primary aim of the study was to assess the acceptability and 
feasibility of the proposed intervention trial in terms of recruitment rate 
and time taken to complete the recruitment, adherence, adverse effects 
and process evaluation. This was achieved through documentation of 
adherence to the intervention and measurement protocol, recording of 
any adverse events, as well as measurements of changes in health out-
comes that may occur during the intervention period. 
4.2. Secondary 
The study protocol includes the investigation of changes in:  
 Cognitive function  
 Cerebral blood flow  
 Resting clinic and home BP  
 Nitric oxide biomarkers (urinary, plasma and salivary NO2
  and NO3
  , 
NO exhaled and whole-body NO production using stable isotopic 
methods)  
 Validation of salivary NO strips for the long-term compliance to NO3
 
-based nutritional interventions  
 Metabolic risk factors (glucose, insulin)  
 Oxidative stress biomarkers (3-Nitrotyrosine)  
 Inflammatory biomarkers (IL-6)  
 Endothelial-dependent and independent microvascular blood flow, 
measured by Laser Doppler Iontophoresis (LDI).  
 Pulmonary function measured by portable spirometer 
4.3. Compliance with the intervention 
All participants were provided with verbal and written instructions 
on the tasks to be completed at home during the trial. Participant 
compliance was checked primarily by a daily compliance log which was 
used to record the time they consumed the BJ. In addition, they were 
asked to return any unopened bottles to the study team. After six weeks, 
participants returned to the research centre for a mid-study assessment 
visit to check their compliance, to collect information on safety and 
adverse events that may have occurred during the first part of the study 
and to provide participants with the final batch of BJ bottles to complete 
the study. 
Fig. 1. Overview of the protocol for the collection of the biological samples during the study.  
A.M. Babateen et al.                                                                                                                                                                                                                           
Contemporary Clinical Trials Communications 18 (2020) 100571
5
Compliance with the intervention was also assessed objectively by 
measuring dietary NO3
  and NO2
  concentrations in plasma, saliva and 
urine samples and using salivary strips. Plasma samples were collected 
at baseline and 13 weeks. Salivary strips and urine and saliva samples 
were collected for 3 consecutive days every 4 weeks. The protocol for the 
collection of the biological samples is described in Fig. 1. The mea-
surement of NO3
  /NO2
  concentrations were taken as a measure of the 
adherence to the intervention and it is expected to find greater con-
centrations in these biomarkers in the samples collected from high NO3
 
dose group compared to lower NO3
  dose groups and placebo. 
Salivary NO strips were also collected concomitantly with the 
collection of the saliva samples as part of a validation sub-study to assess 
the utility of this non-invasive method for the assessment of compliance 
to prolonged NO3
  -based nutritional interventions. The colour of the 
salivary strips was read immediately after receiving them to determine 
salivary NO2
  concentrations. All participants were instructed not to 
change their dietary habits or physical activity and to avoid using 
mouthwash during the study. 
4.4. Data collection 
Socio-demographic, lifestyle and medical history: A questionnaire was 
used to collect detailed information on any previous or current illnesses, 
prescribed and non-prescribed medication use, smoking habits, educa-
tion and alcohol intake. 
Feasibility and acceptability: Feasibility was evaluated by assessing 
recruitment and retention rates, time taken for recruitment, and number 
of dropouts, with reasons. In addition, adherence to the intervention and 
compliance with other components of the protocol to be completed at 
home were evaluated. Completeness of recording of the outcome mea-
sures was reported. Acceptability was evaluated by obtaining feedback 
from participants on the nutritional interventions and measurement 
protocols as well as reporting the reasons for discontinuation of the 
intervention. 
Anthropometry and body composition: Height was measured to the 
nearest 0.5 cm at the screening visit using a stadiometer with an 
adjustable headpiece. Body weight and body composition parameters 
(fat mass, fat free mass, body fat % and total body water) were assessed 
at baseline and at the end of the study by bioelectrical impedance 
analysis (Tanita BC420 MA, Tanita Corporation, Tokyo, Japan). Weight 
and height were used to calculate Body Mass Index (BMI). Waist 
circumference at the midpoint between the lowest margin of the last rib 
and the top of the iliac crest was measured at baseline and end of the 
study. 
Blood pressure: Resting clinic blood pressure was measured using an 
automated monitor (model: Omron M3 [HEM-7200-E8(V)]). Partici-
pants were in a supine position and measurements were performed after 
participants had rested for at least 10 min. Three blood pressure mea-
surements were taken and the average of the three readings was calcu-
lated. Home resting blood pressure was also measured using the same 
monitor at baseline and end of the study as part of the protocol for the 
measurement of whole-body NO production. Each participant was asked 
to measure blood pressure after they had collected a saliva sample (eight 
measurements in total). All participants were asked to rest for about 10 
min before each measurement (see below for more details). 
Peripheral vascular function: Vascular function data were collected at 
baseline and the end of study using Laser Doppler iontophoresis (LDI, 
Moor Instruments, Axminster, UK). LDI has been shown to provide a 
valid measure of skin blood flow [15,16]. One % acetylcholine (Ach, 
Sigma-Aldrich) and 1% sodium nitroprusside (SNP, Sigma-Aldrich) so-
lution (v/v) were prepared fresh before each visit. One mL of each so-
lution was applied into the iontophoresis chambers placed on the 
forearm of the participants to quantify changes in 
endothelial-dependent and independent microvascular blood flow, 
respectively. Forearm skin erythrocyte flux was measured for 3 min 
prior to the start of the iontophoresis (baseline), for 5 min during Ach 
and SNP delivery by iontophoresis (stimulation, current set at 30 μA) 
and for 10 min after the Ach and SNP delivery (recovery). All assess-
ments were performed with the participant lying supine on a bed. 
Cerebral blood flow: Haemodynamic responses were monitored using 
a frequency domain ‘quantitative’ NIRS system (OxiplexTS Frequency- 
Domain Near-Infrared Tissue Oximeter, ISS Science) at rest and stimu-
lated conditions (i.e. while participants performed computerized 
cognitive function tests including serial subtraction 3 and 7, Stroop 
(congruous & incongruous) and peg and ball tasks, which were mainly 
executive function tasks). NIRS has been used extensively in neurosci-
ence research as it provides measurements of changes in cerebral blood 
oxygenation related to brain activity [17]. These measurements were 
performed at baseline and end of the study. CBF data were collected at a 
rate of 5 Hz. 
Cognitive function: The Computerised Mental Performance Assess-
ment System software (COMPASS, University of Northumbria), which 
has been shown to be sensitive to a range of nutritional interventions 
[18,19], and the Trail Making Tasks A and B, were used to assess 
cognition at baseline and the end of the study. The COMPASS test in-
cludes word presentation, immediate word recall, digit vigilance, 
numeric working memory, choice reaction time, computerized corsi 
blocks, Stroop, peg and ball, delayed word recalls and words recogni-
tion. A description of these cognitive tasks is provided in Supplemental 
Table 1. 
Lung Function: Pulmonary function was assessed using a portable 
spirometer (Micro Spirometer@, Micro Medical Instruments Ltd, UK), at 
baseline and the end of the study. The following variables were recor-
ded: forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) 
and the ratio of the two volumes (FEV1/FVC). In addition, the real-time 
fractional exhaled nitric oxide (FeNO) was assessed using a portable, 
non-invasive, automated device (NIOX VERO@, Circassia AB, UK). 
Dietary Intake: Dietary NO3
  intake during the study was assessed 
using a 24-hr dietary recall every two weeks (6 dietary assessments were 
performed in total) using an online validated platform (Intake 24) [20]. 
Dietary NO3
  intake was calculated by assigning the specific NO3
  content 
for each reported food (from a comprehensive database including the 
NO3
  concentrations from 3498 individual foods and beverages esti-
mated from sixty different countries [21]) and taking into account the 
amount consumed. Dietary NO3
  intake was reported in mg/day. 
5. Collection of biological samples 
5.1. Blood 
Blood samples were collected after an overnight fast (at least 12 h) at 
baseline and at 13 weeks post-dose. Blood samples were collected by 
venepuncture by trained phlebotomists in 3 tubes (4 ml each), con-
taining (LH) lithium heparin, EDTA (Ethylenediaminetetraacetic acid) 
and sodium fluoride and potassium oxalate, respectively. 
The samples were processed within 10 min of collection to minimize 
nitrite degradation. Samples were spun at 4000 rpm for 10 min at room 
temperature and plasma aliquots were stored at   80 C until further 
analysis. Samples were used to measure the concentrations of NO3
  , NO2, 
cGMP, glucose, insulin, 3-nitrotyrosine (a marker of oxidative stress) 
and Interleukin-6 (a pro-inflammatory marker). 
5.2. Urine and saliva samples and salivary nitrite strips 
Salivary nitrite strips, urine and saliva samples were collected at 
baseline and then again at 4 weeks (3 consecutive days), 8 weeks (3 
consecutive days), and 13 weeks post-dose (see Fig. 1). 
5.3. Urine 
A mid-stream urine sample was collected at the baseline and end of 
study visits using a sterile, collection kit (Mid-stream urine collection 
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set, UN252, Shermond, UK). After 4 and 8 weeks, urine samples were 
collected at home by each participant for three consecutive days using a 
urine collection kit. A pre-paid box with sealed envelopes for the storage 
of biological samples was provided and each participant was asked to 
mail the samples to the research team using a fast delivery service. 
During each three-day collection period, participants were asked to keep 
urine samples in the fridge. All urine samples were stored at   20 C until 
further analyses. Urine samples were used for the measurement of NO3
 
concentrations using ozone-based chemiluminescence. 
5.4. Saliva 
Participants were asked to chew a cotton ball for approximately 2 
min, which was then placed in the barrel of a 20 mL syringe. The plunger 
was then inserted back into the syringe and used to squeeze the saliva 
into a 2 mL Eppendorf tube. Participants were asked to repeat this saliva 
collection procedure at home as required by the study protocol. Samples 
collected after 4 and 8 weeks were posted [together with urine samples 
(see above)], and participants were instructed to keep the saliva samples 
in the freezer until put in the post. After arrival in the laboratory, saliva 
samples were stored at   20 C until required for analysis of NO3
  and 
NO2
  concentrations using ozone-based chemiluminescence and sialin 
concentrations using an ELISA kit (BioAssay™ (Human), Stratech Sci-
entific Ltd, Cambridge, UK). 
5.5. Salivary nitrite strips 
Berkeley strips (Berkeley Test®, CA, USA) were used as per the 
manufacturer’s guidelines. Specifically, participants were asked to place 
the test strip with the ‘saliva here’ side on the tongue and swab it over a 
10 s period covering different areas including the dorsal surface of the 
tongue. The two ends of the strip were folded and pressed gently for 10 s. 
The colour of the NO test pad was then allowed to develop over a 45 s 
period. The intensity of the colour was compared with a colour chart 
included in the product package (Depleted, Low, Threshold, Target and 
High), with darker colours corresponding to higher NO2
  concentrations. 
For the purpose of quantitative analysis, categorical colours were given 
a categorical number from 1 to 5, where 1 corresponding to “Depleted” 
and 5 corresponding to “High”. Participants were asked to repeat a 
similar procedure at home as required by the study protocol. The strips 
collected at 4 and 8 weeks were posted (with the urine and saliva 
samples) to the research centre. Participants were asked to keep the 
strips in a dry place until put in the post. The colour of the strips was 
recorded as soon as they were received in the laboratory. 
5.6. Whole-body NO production 
The measurements of whole-body NO production were performed at 
baseline and at the end of the study. Participant were asked to consume a 
controlled low NO3
  meal at lunch time. Four hours later, a baseline 
saliva sample was collected followed by ingestion of 4 mg of Na15NO3 
dissolved in 100 mL of distilled water. Further saliva samples were 
collected at 6, 7, 8, 9, 18, 19 and 20 h post-meal. NO3
  enrichment in 
saliva was measured using Gas Chromatography Mass Spectrometry 
[22] and NO production will be estimated using a validated model 
proposed by Refs. [6]. 
5.7. Adverse events reporting 
Adverse events are symptoms or signs that may occur during the trial 
and may or may not be causally related to the intervention. All adverse 
events potentially related to the BJ product were recorded. 
5.8. Sample size calculation 
This is a pilot study designed to assess the feasibility and 
acceptability of the proposed intervention. A sample size of 15 per group 
was based on the predicted effect size provided by the study and based 
on the guidelines indicated by Whitehead et al. [23]. This study provides 
guidance on sample size calculation for pilot studies with the aim of 
maximising use of resources and to avoid occurrence of a type II error. 
Specifically, a sample size of 15 individuals per group would provide a 
90% power to detect a medium effect size (δ) between 0.3 and 0.7. 
5.9. Statistical analysis 
Baseline characteristics are presented as mean  SD. Feasibility was 
evaluated by the effectiveness of the screening process and recruitment 
of participants who met the eligibility criteria for the study, together 
with retention of participants. Retention was evaluated by collection of 
information on the proportion of participants lost after randomization in 
each arm of the study. Compliance with the interventions was estimated 
by calculating the proportion of BJ bottles returned unused relative to 
the dispensed bottles. 
5.10. Confidentiality 
Every effort was made to ensure confidentiality. In this study, paper 
forms are stored in locked filing cabinets and transferred to password 
secured computer databases accessible only to the researchers. Partici-
pant data were anonymised by assigning a unique identification code 
which was used on all documents and electronic databases used in the 
study. 
6. Results 
6.1. Recruitment 
In total, 250 responses were received from use of our various 
recruitment methods. As shown in Fig. 2, advertisement via Facebook 
generated the highest response rate with 77 contacts (31%) made within 
a period of 10 days, followed by 68 contacts (28%) established from 
recruitment emails that were sent to participants in previous studies 
who were identified from our databases, 61 responses (24%) from local 
newspapers, 13 responses (5%) received through the advertisement on 
the Voice website (https://www.ncl.ac.uk/nica/voice/), 12 responses 
(5%) from advertisement in the Cathedral church of St Mary newsletter, 
11 responses (4%) received after referral by current participants. The 
least effective strategy was the distribution of flyers, from which only 7 
responses (3%) were received. 
Fig. 3 summarizes the recruitment and retention of participants in 
the study. A hundred and six participants were either unreachable or 
declined to participate. The initial telephone screening was conducted 
with 144 individuals. At this stage, 68 potential participants were not 
Fig. 2. Response rate from each recruitment strategy.  
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included for the following reasons: 1) taking medications such as ant-
acids, antidepressants or diuretics (54%), 2) co-existent health condi-
tions including cancers, cardiovascular disease, kidney disease, type 1 
diabetes or epilepsy (19%), 3) declined to take part after reading the 
information sheet (12%), 4) unreachable (6%), 5) smokers (4%) and 6) 
age over 75 years old (4%). 
A total of 76 participants attended the on-site screening visit to 
confirm their eligibility. Seventy of these persons were eligible and 62 
participants were consented and enrolled. Nine participants (11%) were 
excluded at the screening visit, and the reasons included high BP (55%), 
normal BMI < 24.9 kg/m2 (33%) and BMI > 40 mg/m2 (11%). Addi-
tional reasons to not participate included: 1) no longer interested to take 
part (4%), 2) personal bereavement (1%) and 3) being unwell (1%). The 
recruitment target was 60 participants, but two participants who drop-
ped out the study immediately after the start of the intervention were 
replaced and, therefore, 62 participants were randomized and had a 
baseline visit assessment. 
The sixty-two participants were randomized to one of the four 
intervention groups as follows: 16 participants were allocated to Group 
1 (2 shots of BJ/day, every morning and evening), 17 participants to 
Group 2 (1 shots of BJ/day, every evening), 14 participants to Group 3 
(1 shot of BJ every other evening) and 15 participants were allocated to 
Group 4 (Placebo, 1 shot of BJ depleted NO3
  every other evening). 
6.2. Retention 
Of those who were randomly assigned to Group 1 (n  16), 10 par-
ticipants completed their 13 weeks assessment. Similarly, 13, 14, and 13 
participants from Groups 2, 3 and 4 completed their 13 weeks assess-
ment. The overall attrition rate for the study was 19% with 12 partici-
pants dropping from the study. 
6.3. Baseline characteristics of participants 
Baseline characteristics of the participants are reported in Table 2. 
The age of participants ranged from 60 to 73 years (mean  SD, 66  4 
years) and 62% were men (n  38). All included participants were either 
overweight (n  35) or obese (n  27). BMI for all randomized partic-
ipants ranged from 25 to 39 kg/m2 (30.4  4 kg/m2). The range of SBP 
was from 110 to 167 mmHg (mean 135  15 mmHg). The range of DBP 
was from 60 to 100 mmHg (mean 77  10 mmHg). 
7. Discussion 
There has been a growing research interest into the investigation of 
the potential beneficial effects of NO3
  on cardio-metabolic health out-
comes including blood pressure, glucose control, dyslipidaemia, cogni-
tion, heart failure and peripheral arterial diseases [12,24–27]. However, 
these studies had limited power due to the small sample sizes and the 
duration of the studies was short (<8 weeks). To the best our knowledge, 
this is the longest RCT evaluating the feasibility and potential beneficial 
effects of different doses of NO3
  -rich BJ supplementation on cognitive 
and vascular functions, CBF and pulmonary functions in overweight and 
obese older adults. The study involved a mixed-method approach where 
the primary outcomes on feasibility and adherence were evaluated by 
asking participants to complete detailed questionnaires with closed and 
open questions. Questions focussed on process evaluation, adherence to 
nutritional interventions and measurement protocols, safety of the 
intervention and procedures and suggestions for future studies. An exit 
questionnaire was also administered to participants who dropped out of 
the study asking to explain the reasons for their withdrawal and to 
provide feedback and suggestions for future studies. Objective measures 
of adherence were number of dropouts and completion of daily logs to 
Fig. 3. Flowchart describing the recruitment of participants into the feasibility study.  
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record BJ consumption. In addition, we asked participants to complete 
online 24-hr dietary recalls every 4 weeks and to collect biological 
samples (urine, saliva and salivary strips) to measure changes in NO3
 
concentrations to provide objective evaluation of compliance with the 
interventions. Additional strengths of the study include a detailed 
assessment of physiological outcomes using advanced methods for the 
measurement of cognitive function, peripheral and central vascular 
function, clinic and home measurements of resting blood pressure and 
measurement of nitrate and nitrite concentrations using ozone-based 
chemiluminescence. In addition, this is the first study to employ a 
non-invasive stable isotopic method for the evaluation of changes in 
systemic NO production following prolonged NO3
  supplementation. 
The most challenging aspects of the study included recruiting older 
participants who met our inclusion criteria and in retaining them in the 
trial. Some of the difficulties associated with recruiting older people in 
clinical trials have been documented [28]. We employed a variety of 
recruitment strategies over a 10-month period and we found that 
advertising the study on social media (i.e. Facebook) was the most 
effective strategy. This approach yielded a high response rate within a 
short period of time and we believe that this recruitment strategy may 
represent a viable approach to enrol older participants from the com-
munity in future nutritional and clinical studies. The use of social media 
by older people is increasing [29]. In the UK in 2017, 39% of those aged 
65–74years used a smartphone and 48% of internet users in this age 
group have a social media profile [30]. A recent study indicated that the 
response rate from older people to a social media advertisement for 
recruiting participants into a clinical trial was higher than for younger 
adults [31]. Another recent study reported that the use of social media 
was a successful strategy for recruiting older participants into a clinical 
trial investigating cardiovascular outcomes [32]. We also recruited 
participants from a database of participants who had participated pre-
viously in other studies at Newcastle University and who had expressed 
an interest to be involved in future research. This approach was also 
effective in recruiting participants into the trial, but it was more 
time-consuming, and it had a lower response rate compared with the 
social-media approach. The RCT was also promoted in local newspapers, 
but the response rate was lower, and the costs of the advertisement were 
considerably higher than the social media approach. Overall, the use of 
social media (i.e., Facebook, Twitter) appears to offer a cost-effective 
solution to facilitate the recruitment of older overweight and obese 
participants from the community into a RCT. 
There is limited evidence on the long-term effect of dietary NO3
  on 
physiological functions in older populations. This feasibility study will 
inform the design and conduct of definitive, larger and longer studies 
investigating the effects of nitrate-rich BJ on cognitive and vascular 
outcomes in older people. 
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